title: Solubilization of an adenosine uptake site in brain.
abstract: Procedures are described for the solubilization of adenosine uptake sites in guinea pig and rat brain tissue. Using [3H]nitrobenzylthioinosine [( 3H]NBI) the solubilized site is characterized both kinetically and pharmacologically. The binding is dependent on protein concentration and is saturable, reversible, specific, and high affinity in nature. The KD and Bmax of guinea pig extracts are 0.13 +/- 0.02 nM and 133 +/- 18 fmol/mg protein, respectively, with linear Scatchard plots obtained routinely. Similar kinetic parameters are observed in rat brain. Adenosine uptake inhibitors are the most potent inhibitors of [3H]NBI binding with the following order of potency, dilazep greater than hexobendine greater than dipyridamole. Adenosine receptor ligands are much less potent inhibitors of binding, and caffeine is without effect. The solubilized adenosine uptake site is, therefore, shown to have virtually identical properties to the native membrane site. The binding of the adenosine A1 receptor agonist [3H]cyclohexyladenosine [( 3H]CHA) to the solubilized brain extract was also studied and compared with that of [3H]NBI. In contrast to the [3H]NBI binding site [3H]CHA binds to two apparent populations of adenosine receptor, a high-affinity site with a KD of 0.32 +/- 0.06 nM and a Bmax of 105 +/- 30 fmol/mg protein and a lower-affinity site with a KD of 5.50 +/- 0.52 nM and Bmax of 300 +/- 55 fmol/mg protein. The pharmacology of the [3H]CHA binding site is consistent with that of the adenosine receptor and quite distinct from that of the uptake [( 3H]NBI binding) site. Therefore, we show that the adenosine uptake site can be solubilized and that it retains both its binding and pharmacologic properties in the solubilized state.
authors.forename: A
authors.initials: A
authors.lastname: Verma
authors.forename: M
authors.initials: M
authors.lastname: Houston
authors.forename: P J
authors.initials: PJ
authors.lastname: Marangos
mesh_terms: D000241:Adenosine / Q000031:analogs & derivatives / Q000378:metabolism* / Q000494:pharmacology; D000818:Animals; D001569:Benzodiazepines / Q000494:pharmacology; D001665:Binding Sites; D001921:Brain / Q000378:metabolism*; D002462:Cell Membrane / Q000378:metabolism; D004285:Dogs; D004912:Erythrocytes / Q000378:metabolism; D005990:Glycerol / Q000494:pharmacology; D006168:Guinea Pigs; D006367:HeLa Cells / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D051381:Rats; D011956:Receptors, Cell Surface / Q000378:metabolism; D011983:Receptors, Purinergic; D013868:Thioinosine / Q000031:analogs & derivatives / Q000378:metabolism
chemical_list: D011956:Receptors, Cell Surface; D011983:Receptors, Purinergic; D001569:Benzodiazepines; C027513:N(6)-cyclohexyladenosine; D013868:Thioinosine; C001789:4-nitrobenzylthioinosine; D000241:Adenosine; D005990:Glycerol